Abstract
We present the case of an HIV/HCV-coinfected patient with HIV-related pulmonary hypertension (HRPH) who experienced a good clinical and functional response to bosentan, with a subsequent switch to oral sildenafil due to increased transaminase levels. Bosentan resulted less handy in this case, probably due to both side effects and co-morbidities.
Highlights
Abstract ly We present the case of an HIV/HCV-coinfectn ed patient with HIV-related pulmonary hypero tension (HRPH) who experienced a good cline ical and functional response to bosentan, with s a subsequent switch to oral sildenafil due to u increased transaminase levels
In January 2008 the patient underwent a third drugs currently approved as specific therapy estimated systolic PAP (sPAP) was rarely evaluable because cardiac catheterization that showed a further for pulmonary arterial hypertension (PAH) include the prostacyclin analogues, the endothelin receptor antagonists, and the oral phosphodiesterase type 5 (PDE5) inhibitors
There is increasing evidence of 2007 the patient underwent a new cardiac 9th, 2008 she was last evaluated by the the efficacy of bosentan in the treatment of HRPH patients.[3]
Summary
Discussion protease inhibitor-based ART regimens since py. Bosentan resulted less handy in this case, saquinavir, indinavir and ritonavir probably due to both side effects and co-morsignificantly modify the pharmacokinetics of bidities. -c demonstrated improvements in exercise tolerance and haemodynamics.[15,16] Only one case of n sitaxsentan therapy in a HRPH patient has o been reported to date.[17] The drug has subseN quently been withdrawn from the market due CD4 cells count, based on the observation by Opravil and coll. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. In a double-blinded placebo-controlled study, PDE-5 inhibitor sildenafil was demonstrated to improve exercise capacity, functional class and haemodynamics in patients with PAH.[18].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
